Request Sample Inquiry
Lung Cancer Screening Software Market

Lung Cancer Screening Software Market

Lung Cancer Screening Software Market - Global Industry Assessment & Forecast

Number Of Pages # Pages:


Base Year:



Jul - 2024



Report Code:


Segments Covered
  • By Mode of Delivery By Mode of Delivery Cloud Based Solutions, On-Premise Solutions, Web Based Solutions
  • By Product By Product Lung Cancer Screening Radiology Solution, Lung Cancer Screening Patient Management Software, Nodule Management Software, Data Collection and Reporting, Patient Coordination and Workflow, Lung Nodule Computer Aided Detection, Pathology and Cancer Staging, Statistical Audit Reporting, Screening PACs, Practice Management, Audit Log Tracking
  • By Type By Type Computer-Assisted Screening, Traditional Screening
  • By Application By Application Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
  • By Platform By Platform Standalone, Integrated
  • By Purchase Mode By Purchase Mode Institutional, Individual
  • By End User By End User Oncology Centers, Hospitals, Ambulatory Surgical Centers, Other End Users
  • By Distribution Channel By Distribution Channel Direct Tender, Third Party Distributors
  • By Region By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Base YearBase Year: 2023
Forecast YearsForecast Years: 2024 - 2032
Historical YearsHistorical Years: 2018 - 2022
Revenue 2023Revenue 2023: USD 30.2 Million
Revenue 2032Revenue 2032: USD 146.32 Million
Revenue CAGRRevenue CAGR (2024 - 2032): 19.2%
Fastest Growing Region Fastest Growing Region (2024 - 2032) Asia Pacific
Largest Region Largest Region (2023): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst
Lung Cancer Screening Software Market Share

The global Lung Cancer Screening Software Market is valued at USD 30.2 Million in 2023 and is projected to reach a value of USD 146.32 Million by 2032 at a CAGR (Compound Annual Growth Rate) of 19.2% between 2024 and 2032.

Key highlights:

  • The North American region asserted its dominance in the Lung Cancer Screening Software market in 2023, seizing a commanding 44.5% share of the total revenue,
  • The Asia Pacific region is poised for significant growth, with a notable projected Compound Annual Growth Rate (CAGR) over the forecast period,
  • The Cloud-Based Solutions segment emerged as the frontrunner in the market landscape in 2023, commanding a substantial share of 55.4%,
  • The Non-Small Cell Lung Cancer (NSCLC) segment maintained its stronghold, capturing a leading market share of 77.5% in the Lung Cancer Screening Software market for 2023,
  • Standalone platforms emerged as the market leader in 2023, claiming a dominant 61.5% share of the market,
  • Institutional purchase mode asserted its prominence in 2023, accounting for an impressive 65.3% market share,
  • The integration of the AI and ML not only enhances diagnostic accuracy but also streamlines workflows, enabling healthcare professionals to deliver timely and personalized care to patients, driving the Lung Cancer Screening Software market.

Lung Cancer Screening Software Market Size, 2023 To 2032 (USD Million)

AI (GPT) is here !!! Ask questions about Lung Cancer Screening Software Market

Regional Overview:

North America Dominated Sales with a 44.5% share in 2023. According to the American Cancer Society (ACS) data published in 2022, lung cancer (both small and non-small cell) is the second most common cancer in both men and women, accounting for nearly 25% of all cancer deaths. The high prevalence of lung cancer drives demand for advanced screening technologies to facilitate early detection and improve treatment outcomes.

The proliferation of screening initiatives, the rising acceptance of software solutions for patient care, heightened demand for screening via chest radiography, and the extensive establishment of screening facilities further drive the market for Lung Cancer Screening Software. The market is progressing considerably due to the increase in research and clinical trials evaluating cancer screening software's effectiveness. Adopting such technologies for effective patient care is further facilitated by the notable prevalence of multiple screening programs. In addition, the increasing number of research studies and clinical trials conducted to examine program efficacy increases the need for this kind of software. For instance, the National Lung Screening Study (NLST), which was started in the United States, functioned as an annual screening-focused randomized experiment. It aimed to evaluate chest radiographs and low-dose computed tomography (LDCT) in high-risk people.

The demand for software solutions designed to optimize workflow management is mostly driven by the region's abundance of screening facilities and its growing target demographic. Interestingly, there are an estimated 1,800 screening centers in the United States, which increases the demand for efficient workflow solutions. Furthermore, the implementation of favorable government programs and the increased awareness around lung cancer detection also play a key role in the market's growth. For instance, the American Lung Association and the American Thoracic Society (ATS) unveiled a new screening implementation guide during the ATS 2018 International Conference.

In addition to favorable regulatory conditions and robust healthcare infrastructure, North America benefits from the presence of leading market players that drive innovation and competition. Companies like GE Healthcare, Intelerad Medical Systems, Siemens Healthineers, and Optellum are at the forefront of developing advanced lung cancer screening software solutions tailored to the needs of healthcare providers and patients in the region. These companies leverage their expertise, resources, and extensive networks to enhance the accessibility and effectiveness of lung cancer screening across North America. Collaborations between academic institutions, research organizations, and industry stakeholders drive innovation, introducing novel AI-driven solutions and multimodal data integration platforms. For instance, In August 2022, Intelerad Medical Systems acquired PenRad Technologies, Inc., a software company specializing in breast imaging and lung screening productivity. This acquisition broadened Intelerad’s product portfolio in mammography and lung analytics, optimizing workflow for radiologists and improving patient health outcomes.

U.S. Lung Cancer Screening Software Market Overview

The U.S. Lung Cancer Screening Software market, valued at USD 10.87 Million in 2023 to USD 53.4 Million in 2032, is anticipated to grow at a CAGR of 19.35% from 2024 to 2032.

According to the American Cancer Society's 2023 report, the majority of lung cancer diagnoses occur in individuals aged 65 and above, with the average age at diagnosis hovering around 70 years. The United States is propelled by a rising number of individuals suffering from lung cancer alongside an aging population. The Lung Cancer Screening Software market has grown significantly in recent years, mainly due to technological developments and an increasing focus on early detection and prevention. Since lung cancer is still one of the top causes of cancer-related mortality in the US, there is more emphasis on efficient screening techniques. As a result, healthcare professionals use software solutions more frequently to improve the precision and effectiveness of lung cancer screening procedures.

Lung cancer screening software has been transformed by the use of artificial intelligence (AI) and machine learning algorithms, which allow for the more accurate identification of errors in medical imaging data, such as CT scans. These technologies have improved patient outcomes and survival rates by enabling medical personnel to recognize possible cancers early on. Furthermore, AI-driven software may swiftly analyze large volumes of imaging data, enabling prompt diagnosis and treatment planning.

Integrating cloud-based platforms in the U.S. Lung Cancer Screening Software market offers numerous benefits, such as centralized data storage, easy accessibility, and scalability. By utilizing cloud-based solutions, healthcare practitioners may effectively handle substantial patient data sets, work with interdisciplinary teams, and guarantee regulatory compliance. This shift toward cloud-based technologies reflects the industry's continuous attempts to improve patient care delivery and streamline workflows.

Application Overview:

In 2023, the Non-Small Cell Lung Cancer (NSCLC) segment dominated the market with the largest share of 77.5%. The Lung Cancer Screening Software market, segmented by the Application, includes Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

The Non-Small Cell Lung Cancer encompasses various subtypes such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Screening software designed specifically to identify and treat non-small cell lung cancer (NSCLC) is widely used. It dominates the market because it is essential for early diagnosis, prognosis, and therapeutic decision-making.

The non-small cell lung cancer (NSCLC) category emerged as the top revenue generator, propelled by heightened screening awareness in both developed and developing nations and the escalating incidence of NSCLC worldwide. For instance, data from the American Cancer Society reveals that approximately 84% of lung cancer cases are attributed to non-small cell lung cancer. Moreover, a notable discrepancy in survival rates, with NSCLC boasting a five-year survival rate of 24%.

Globally, the rise in harmful habits like smoking, drinking alcohol, using supplements excessively, and leading sedentary lives are all contributing factors to the growth of the NSCLC segment. Global statistics from December 2022 reveal approximately 2.20 million new cases, with projections indicating a doubling of this figure by 2025. This growing burden of lung cancer underscores the demand for effective treatment options, thereby fueling market expansion.

Screening software solutions for non-small cell lung cancer (NSCLC) focus on enabling lung nodule detection easier, evaluating radiographic images, and giving medical professionals decision support tools. These software programs improve the precision and efficacy of lung cancer diagnosis using complex algorithms, including machine learning and artificial intelligence. These applications greatly enhance patient outcomes and lower lung cancer-related death rates by facilitating the early detection of NSCLC lesions and aiding in risk stratification.

The dominance of the NSCLC segment reflects the broader trend in oncology towards personalized medicine and targeted therapies. Screening software applications for NSCLC often incorporate genomic and molecular data to guide treatment selection and predict therapeutic response. This personalized approach allows clinicians to tailor treatment plans based on the specific characteristics of each patient's tumor, maximizing efficacy while minimizing adverse effects.

The growth of the Lung Cancer Screening Software market has been significantly impacted by the COVID-19 pandemic. For instance, reported that as of July 2023, over 200 interventional studies were halted during the pandemic, causing a slowdown in market growth. However, with the easing of restrictions and the resumption of services, there has been a renewed focus on conducting clinical trials for NSCLC treatment. For instance, in October 2022, Daiichi Sankyo, Inc., in collaboration with AstraZeneca, initiated a Phase II clinical trial to assess the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic NSCLC. Such activities are expected to drive market growth over the forecast period.

Government Initiatives:

  • In 2023, the Health and Social Care Secretary announced a new £21 million fund to provide NHS staff with cutting-edge artificial intelligence (AI) technology to expedite patient diagnosis and treatment. NHS Trusts will be able to vie for funding through the AI Diagnostic Fund, facilitating the accelerated deployment of AI imaging and decision support tools across hospitals. These tools are intended to enhance diagnostic capabilities, particularly for conditions such as cancers, strokes, and heart conditions, enabling quicker and more accurate patient assessments.
  • In 2022, the U.S. Department of Health and Human Services (HHS) has revealed a $5 million funding initiative aimed at advancing equity in cancer screening within community health centers. This investment, administered by HHS's Health Resources and Services Administration, is designed to bolster access to critical cancer screenings, aligning with President Biden's Cancer Moonshot initiative. The initiative underscores the administration's commitment to promoting early detection and treatment as a vital strategy in the fight against cancer, reflecting President Biden's Unity Agenda and his impassioned call for action on cancer screening and early detection to propel the nation closer to the goal of eradicating cancer.
  • The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PMJAY) is a pivotal health insurance scheme in India. It provides comprehensive coverage of up to INR 5 lakhs per family per year across a broad spectrum of medical treatments, including cancer-related care.
  • In 2024, the Health Resources and Services Administration (HRSA) is fortifying its Accelerating Cancer Screening (AxCS) Initiative by injecting an additional $10 million into the Alcee L. Hastings Program for Advanced Cancer Screening. This infusion elevates the total program funding to over $25 million within a span of three years.

Key Trends

  • AI and machine learning are revolutionizing lung cancer screening by enhancing the accuracy and efficiency of detection. AI algorithms can analyze large volumes of CT scan data more quickly and accurately than traditional methods, identifying early signs of lung cancer that may be missed by human radiologists. These technologies are improving the sensitivity and specificity of screening, leading to earlier and more accurate diagnoses.
  • The integration of multimodal data, including imaging, genomic, and clinical data, is becoming increasingly important. Platforms that combine these data sources provide a more comprehensive view of a patient’s condition, enabling better risk stratification and personalized treatment plans. This holistic approach helps in identifying high-risk patients and tailoring interventions more effectively.
  • There is a growing emphasis on early detection and preventive care, driven by the recognition that early-stage lung cancer is more treatable. Public health initiatives and screening programs encourage high-risk populations to undergo regular screenings. Software that supports early detection aligns with these initiatives by providing tools that help identify lung cancer at its earliest and most treatable stages.
  • There is an increasing focus on patient-centric approaches in lung cancer screening. Software that enhances patient engagement provides educational resources and supports shared decision-making is becoming more prevalent. Empowering patients with information and involving them in their care decisions improves compliance and outcomes.

Premium Insights

The escalating incidence of lung cancer worldwide is prompting healthcare providers to seek innovative solutions for early detection and intervention. Lung cancer is the leading cause of cancer-related deaths globally, resulting in the highest mortality rates among both men and women. The imperative for effective screening technologies has never been greater. The Lung Cancer Screening Software market is driven by the expanding smoking population, advancements in screening technologies, and governmental initiatives to bolster early detection efforts. For instance, according to WHO, smoking is the primary cause of lung cancer, accounting for approximately 85% of all cases. Consequently, the market is witnessing heightened investments in research and development to enhance the accuracy and efficiency of screening software.

Advancements in advancements in imaging technology, particularly the widespread adoption of computed tomography (CT) scans, are catalyzing demand for sophisticated screening software. These modern imaging modalities generate vast amounts of data, necessitating advanced algorithms and analytics tools to extract actionable insights effectively. A myriad of innovations, including liquid biopsies, AI analyzers, and synthetic biopsies, are revolutionizing the landscape of cancer detection.

Technological advancements focus primarily on enhancing early detection and accuracy, and numerous research institutions and industry players are spearheading the development of cutting-edge technologies for early-stage cancer detection. For instance, in January 2024, the Massachusetts Institute of Technology unveiled a nanoparticle sensor deliverable via inhaler for lung cancer diagnosis, presenting a potential alternative to existing diagnostic methods, particularly beneficial in regions with limited access to CT scanners. Similarly, in October 2023, Delfi Diagnostics introduced its inaugural liquid biopsy test designed for lung cancer screening.

In addition to technological advancements and healthcare policy initiatives, shifting consumer preferences and patient empowerment are reshaping the landscape of the Lung Cancer Screening Software market. Patients are becoming more proactive in managing their health, demanding access to innovative screening technologies and personalized healthcare experiences. Consequently, market players respond by developing patient-centric software solutions prioritizing usability, accessibility, and patient engagement. For instance, in 2019, Genentech and Roche forged an alliance to explore the potential of biomarker screening in lung cancer treatment and detection.

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

  • Real-Time Data Updates:
  • Competitor Benchmarking
  • Market Trends Heatmap
  • Custom Research Queries
  • Market Sentiment Analysis
  • Demographic and Geographic Insights

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Growing cases of lung cancer globally drive the Lung Cancer Screening Software market

Lung cancer stands as the second most prevalent cancer worldwide, ranking highest among men and second among women. For example, data from the World Health Organization (WHO) indicates a staggering 2.21 million new cases of lung cancer globally, resulting in 1.80 million deaths attributed to the disease. Contributing to this alarming trend are elevated smoking rates, a primary causative factor, along with exposure to secondhand smoke, air pollution, and occupational hazards like asbestos. The aging population further exacerbates the rise in lung cancer cases, with advancements in medical diagnostics leading to improved early detection rates, thus necessitating more surgical interventions and propelling market expansion. Furthermore, in response to the rising prevalence of lung cancer, various cancer institutes are launching awareness campaigns aimed at promoting early detection initiatives. For instance, in November 2023, the Barbara Ann Karmanos Cancer Institute and other organizations nationwide observed November as lung cancer awareness month, highlighting the importance of early screening and detection efforts.

The lack of skilled medical personnel poses a significant restraint to the lung cancer screening software market

This shortage pertains to professionals adept at effectively interpreting and managing the data generated by screening software. The complexity of lung cancer diagnostics requires specialized knowledge and expertise, which, if lacking, can impede the adoption and efficacy of screening software. Moreover, the shortage of skilled personnel can delay screening processes, potentially affecting patient outcomes. Inadequate training and proficiency in utilizing screening software may result in misinterpretation of results or suboptimal patient management, undermining the purpose of early detection and intervention. Additionally, the lack of skilled personnel may limit the scalability and reach of lung cancer screening programs, particularly in underserved regions or communities where access to trained professionals is limited. This disparity can exacerbate existing healthcare inequalities, hindering efforts to reduce the burden of lung cancer on a global scale. Addressing this restraint requires investments in training and education programs to equip healthcare professionals with the necessary skills to utilize lung cancer screening software effectively. Collaborative efforts between healthcare institutions, governments, and technology providers are essential to overcoming this challenge and ensuring the optimal utilization of screening software for improved patient outcomes.

Competitive Landscape

The Lung Cancer Screening Software market is characterized by diverse companies ranging from established medical technology giants to innovative startups. Major players such as GE Healthcare, Siemens Healthineers, and Philips Healthcare dominate the market, leveraging their extensive experience, vast resources, and comprehensive product portfolios. These companies are heavily investing in research and development to enhance their lung cancer screening software's accuracy, efficiency, and user-friendliness. Their strong global presence and established customer bases give them a significant competitive edge, enabling them to offer integrated solutions that combine hardware and software for a seamless screening process.

  • In July 2022, GE Healthcare launched its advanced ultrasound technology, the Voluson Expert 22, significantly advancing its Women's Health portfolio. This cutting-edge product utilizes graphic-based beam former technology to improve image quality and functionality, reinforcing GE Healthcare's status as a premier provider of healthcare products and services.

Strategic partnerships, mergers, and acquisitions further shape the competitive landscape as companies seek to expand their technological capabilities and market reach.

  • In May 2022, BC Cancer launched a lung cancer screening program accessible to eligible high-risk individuals across 36 sites in the province. Targeted at individuals aged 55-74 with a significant smoking history, the program aims to provide equitable access, facilitate early detection, improve survival rates, and maintain high standards of screening and prevention.
  • In June 2020, Roche launched its uPath PD-L1 digital pathology platform for non-small cell lung cancer. The platform utilizes AI to provide pathologists with reproducible assessments, aid diagnosis, and treatment options, and highlight positive and negative tumor cells.

The key players in the global Lung Cancer Screening Software market include - GE Healthcare (U.S.), IBM Watson Health (U.S.), Siemens Healthineers (Germany), Optellum (UK), Philips Healthcare (Netherlands), McKesson Corp. (U.S.), Koninklijke Philips N.V. (Netherlands), Varian Medical Systems (U.S.), Thermo Fisher Scientific Inc. (U.S.), Hologic Inc. (U.S.) among others.

Recent Market Developments

Optellum Unveils AI Guidance Platform for Life Science Research at 2024 ASCO Annual Meeting

  • In 2024, Optellum, a global leader in AI-driven clinical decision support for early lung cancer diagnosis, introduced its multimodal therapy AI guidance platform for life science research. This innovative AI software and scientific findings indicating its potential to enhance curative lung cancer treatment will be unveiled at the 2024 ASCO Annual Meeting in Chicago.

Royal Philips Partners with Biodesix to Enhance Lung Cancer Patient Management System

  • In June 2022, Royal Philips partnered with Biodesix, Inc. to integrate the results of Biodesix’s Nodify Lung blood-based lung nodule risk assessment tests into the Philips Lung Cancer Orchestrator patient management system. This integration of proteomics data with existing radiologic and patient history data aims to enhance diagnostic efficiency for cancer care centers managing the increasing number of lung nodule cases, facilitated by the contextual launch of the Biodesix Nodify Lung application within the Lung Cancer Orchestrator.

DELFI Diagnostics Introduces FirstLook Lung, a High-Accuracy Blood Test for Lung Cancer Detection

  • In October 2023, DELFI Diagnostics launched FirstLook Lung, a blood test for lung cancer detection based on low-dose CT scans. Utilizing fragmentomics, the test offers impressive predictive values of 99.7% for both negative and positive results.

The global Lung Cancer Screening Software market can be categorized as Mode of Delivery, Product, Type, Application, Platform, Purchase Mode, End User, Distribution Channel, and Region.

Parameter Details
Segments Covered

By Mode of Delivery

  • Cloud Based Solutions
  • On-Premise Solutions
  • Web Based Solutions

By Product

  • Lung Cancer Screening Radiology Solution
  • Lung Cancer Screening Patient Management Software
  • Nodule Management Software
  • Data Collection and Reporting
  • Patient Coordination and Workflow
  • Lung Nodule Computer Aided Detection
  • Pathology and Cancer Staging
  • Statistical Audit Reporting
  • Screening PACs
  • Practice Management
  • Audit Log Tracking

By Type

  • Computer-Assisted Screening
  • Traditional Screening

By Application

  • Non-Small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer (SCLC)

By Platform

  • Standalone
  • Integrated

By Purchase Mode

  • Institutional
  • Individual

By End User

  • Oncology Centers
  • Hospitals
  • Ambulatory Surgical Centers
  • Other End Users

By Distribution Channel

  • Direct Tender
  • Third Party Distributors

By Region

  • North America
    • U.S.
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Regions & Countries Covered
  • North America - (U.S., Canada, Mexico)
  • Europe - (U.K., France, Germany, Italy, Spain, Rest Of Europe)
  • Asia Pacific - (China, Japan, India, South Korea, South East Asia, Rest Of Asia Pacific)
  • Latin America - (Brazil, Argentina, Rest Of Latin America)
  • Middle East & Africa - (GCC Countries, South Africa, Rest Of Middle East & Africa)
Companies Covered
  • GE Healthcare (U.S.)
  • IBM Watson Health (U.S.)
  • Siemens Healthineers (Germany)
  • Optellum (UK)
  • Philips Healthcare (Netherlands)
  • McKesson Corp. (U.S.)
  • Koninklijke Philips N.V. (Netherlands)
  • Varian Medical Systems (U.S.)
  • Thermo Fisher Scientific Inc. (U.S.)
  • Hologic Inc. (U.S.)
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market attractiveness analysis by segments and North America, company market share analysis, and COVID-19 impact analysis
Pricing and purchase options Avail of customized purchase options to meet your exact research needs. Explore purchase options

Frequently Asked Question
  • The global Lung Cancer Screening Software valued at USD 30.2 Million in 2023 and is expected to reach USD 146.32 Million in 2032 growing at a CAGR of 19.2%.

  • The prominent players in the market are GE Healthcare (U.S.), IBM Watson Health (U.S.), Siemens Healthineers (Germany), Optellum (UK), Philips Healthcare (Netherlands), McKesson Corp. (U.S.), Koninklijke Philips N.V. (Netherlands), Varian Medical Systems (U.S.), Thermo Fisher Scientific Inc. (U.S.), Hologic Inc. (U.S.).

  • The market is project to grow at a CAGR of 19.2% between 2024 and 2032.

  • The driving factors of the Lung Cancer Screening Software include

  • North America was the leading regional segment of the Lung Cancer Screening Software in 2023.